Copyright © Inderes 2011 - present. All rights reserved.

Nexstim

8.78 EUR

-0.68 %

5,637 following
Corporate customer

NXTMH

First North Finland

Medical Equipment & Services

Health Care

-0.68 %
-30.87 %
-38.17 %
-39.03 %
-31.67 %
+7.07 %
+128.94 %
+30.40 %
-98.55 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
63.33M EUR
Turnover
284.06K EUR
P/E (adj.) (26e)
62.56
EV/EBIT (adj.) (26e)
54.57
P/B (26e)
12.12
EV/S (26e)
5.18
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
11.50 EUR
Updated
2026-02-26
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2026-02-27

Latest extensive report

Released: 2025-06-26

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
30/3
2026

General meeting '26

14/8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
2025 Annual Report published: Nexstim - Press-release The customer interview about the BrainStim Center in California was interesting, especially this part: ”BrainStim will open a new flagship TMS clinic in Van Nuys, California during 2026. The new clinic is designed to accommodate...
3/5/2026, 10:47 AM
by Tim89
40
You see this nTMS everywhere now, both in Finland and elsewhere, so it would be a surprise if this doesn’t benefit the manufacturer of the best device as well. Diamond hands and it will turn out well So we are starting to move into the Early Adoption phase: I don’t believe that even...
3/5/2026, 5:50 PM
by Seeras
29
Forbes also published a good piece on that Alzheimer’s company, which also mentioned Sinaptica: https://www.forbes.com/sites/naveenrao/2026/03/06/105-million-brings-cognito-and-neurotech-to-a-pivotal-stage/ The valuations there are certainly on a different level than in Helsinki....
20 hours ago
by Kyhnykeisari
11
Nexstim has a small stake in Sinaptica… it could prove to be valuable at some point. Nexstim is available at 8.50 today. Is it starting to be time to add?
20 hours ago
by Puutaheinää
10
Now that there isn’t much new to report from Nexstim, here’s something about Sinaptica’s competitor: Longevity.Technology – 5 Mar 26 Cognito lands $105m for sensory stimulation Alzheimer’s therapy Company targets regulatory submission and commercialization of non-invasive treatment...
20 hours ago
by AccionHombre
7
Thanks, I missed this change in the disclosure policy during the webinar.
3/5/2026, 9:16 AM
by Puutaheinää
6
Medical tech should otherwise be immune, but rising interest rates obviously have an impact. I’m still a bit surprised that they are among the top decliners.
17 hours ago
by Puutaheinää
4
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.